Millers of Wyckoff, Inc., Wyckoff, NJ

Is Millers of Wyckoff, Inc. registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Millers of Wyckoff, Inc. hold a New Jersey pharmacy license?

State board of pharmacy records for New Jersey are not checked: the Division of Consumer Affairs website, which publishes pharmacy permit records and board actions, answers automated requests with a bot challenge, and the state’s public license lookup lists individual licensees but not pharmacy permits; this index does not work around blocks. The Texas State Board of Pharmacy also lists nonresident license 35591 for MILLERS OF WYCKOFF INC, WYCKOFF, NJ, status Active, as of Nov 15, 2026. The California State Board of Pharmacy also lists nonresident license NRP 2219 for Millers Of Wyckoff Inc, Wyckoff, NJ, status Active, as of Nov 6, 2026. The Colorado State Board of Pharmacy also lists nonresident license OSP 6085 for Millers of Wyckoff Inc, Wyckoff, NJ, status Active, as of Nov 15, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054023595 for MILLERS OF WYCKOFF INC, WYCKOFF, NJ, status ACTIVE, license 054018003 for MILLERS OF WYCKOFF INC, WYCKOFF, NJ, status CHANGE OF OWNERSHIP, license 054021124 for MILLERS OF WYCKOFF INC, WYCKOFF, NJ, status CHANGE OF OWNERSHIP and license 054023471 for MILLERS OF WYCKOFF INC, WYCKOFF, NJ, status CHANGE OF OWNERSHIP, as of Nov 13, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0000894 for MILLERS OF WYCKOFF, WYCKOFF, NJ, status ACTIVE (CURRENT), as of Nov 15, 2026. The Delaware Division of Professional Regulation also lists nonresident license A9-0013192 for Millers of Wyckoff, WYCKOFF, NJ, status Active, license A9-0001121 for Millers of Wyckoff, Wyckoff, NJ, status Closed and license A9-0002292 for Millers of Wyckoff, WYCKOFF, NJ, status Closed, as of Nov 10, 2026. The Michigan Department of Licensing and Regulatory Affairs also lists nonresident license 5301009862 for Millers of Wyckoff, Inc., Wyckoff, NJ, status Active, as of Nov 10, 2026.

Has Millers of Wyckoff, Inc. had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter close-out (Feb 26, 2019), 1 untitled letter (Dec 1, 2021), 1 state referral letter (Feb 26, 2019) and 2 FMD-145 letters (Feb 26, 2019 and Jun 17, 2022) for Millers of Wyckoff, Inc. State board of pharmacy records for New Jersey are not checked: the Division of Consumer Affairs website, which publishes pharmacy permit records and board actions, answers automated requests with a bot challenge, and the state’s public license lookup lists individual licensees but not pharmacy permits; this index does not work around blocks. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Millers of Wyckoff, Inc.
Location
Wyckoff, NJ
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
0
Latest action on that page
Jun 17, 2022
FDA Data Dashboard inspections
3 inspections: 2 OAI, 1 VAI; 3 published Form 483s
Form 483 text on this page
2 Form 483s, 14 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Millers of Wyckoff, Inc., a 503A facility, with 6 dated actions.

Document
Jun 17, 2022FMD-145 letterFMD-145 Letter Issued 06/17/2022Not linked by FDA
Dec 1, 2021Untitled letterUntitled Letter Issued 12/01/2021FDA copy (archived)
Oct 9, 2020Form 483483 Issued 10/09/2020FDA copy (archived)
Feb 26, 2019Warning letter close-outWarning Letter CloseOut (02/26/2019)FDA copy (archived)
Feb 26, 2019FMD-145 letterFMD-145 Letter Issued 02/26/2019FDA copy (archived)
Feb 26, 2019State referral letterState Referral Letter Issued 02/26/2019FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Millers of Wyckoff, Inc., Wyckoff, NJ (FEI number 3004600183), matched to this page by exact name, city and state. It lists 3 inspections: 2 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Oct 9, 2020Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30046001831132682
May 18, 2017Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30046001831018468
Jul 16, 2015Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3004600183934124

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 14 numbered observations in all, across 2 inspections ending Jul 16, 2015 to Oct 9, 2020. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Sep 16, 2020 to Oct 9, 2020: 2 observations

Firm on the cover
Millers of Wyckoff, Inc, 678 Wyckoff Avenue, Wyckoff, NJ, 07481
FEI number
3004600183
Establishment type on the cover
Producer of Sterile and Non-Sterile Drugs
FDA district office on the cover
Division of Pharmaceutical Quality Operations 110 Waterview Blvd, 3rd Floor Parsippany, NJ 07054
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Hazardous drugs were produced without providing adequate cleaning of utensils to prevent cross contamination.

Specifically, your firm produces potent drugs including, but not limited to Progesterone, Testosterone, or a combination of these drug products from <Redacted B4> Active Pharmaceutical Ingredients (APis). Utensils used in the production of these potent drugs, such as, spatulas, jars and glass beakers are not dedicated and not cleaned with a process that utilizes an agent to deactivate residual APis.

Your firm utilizes a store-bought brand liquid dish detergent and potable water for cleaning of theses utensils in the processing of potent APis. The following potent drug products were observed being prepared and produced using the non-sterile hazard production room on 09/l7/2020:

A) Testosterone Topical 50mg/gm 15% Cream Rx: <Redacted B6> Lot# 09172020@22, BUD: 10/22/2020, Date Made: 09/17/2020

l

B.) BIEST <Redacted B4> Progesterone 2mg/100mg, Rx: <Redacted B6> Lot# 09172020@15, BUD: 12/16/2020, Date Made: 09/17/2020

15 4 C.) BIEST <Redacted B4> Progesterone 2.5mg/125mg, RX: <Redacted B6> Lot# 09172020@25, BUD: 12/16/2020, Date Made: 09/17/2020

Observation 2

Inadequate pressure differentials between higher quality air rooms and lower quality air rooms were observed.

Specifically, your records of differential room pressures are inadequate, in that, you do not record the quantitative value of the pressures. Additionally, your record of differential room pressures failed to record pressure excursions for your Sterile Hazardous Room in the following instances:

Your most recent cleanroom certification report, dated: 08/14/2020, documents that the Sterile Hazardous Room (ISO 7) pressure was recorded at (negative)-0.064" w.c. According to your specification, the acceptance range for differential pressure of this room is between <Redacted B4> In this instance, the reported differential pressure reading was out of specification. However, you continued to use this room as well as, adjacent cleanrooms for production of sterile drug products.

In addition, on 09/25/2020, I observed that the Magnahelic equipment used to monitor the pressure differential reading for the Hazardous Room was (negative) -0.11" w.c, which was not within specifications.

Inspection Jun 29, 2015 to Jul 16, 2015: 12 observations

Firm on the cover
Millers of Wyckoff, Inc., 678 Wyckoff Ave, Wyckoff, NJ 07481 - 1430
FEI number
3004600183
Establishment type on the cover
Producer of Sterile Drugs
FDA district office on the cover
10 Waterview Blvd., 3rd Floor Parsippany, NJ 07054
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written, and followed.

Specifically, the following poor aseptic techniques were observed during processing on 6/29/20 I5 and 6/30/2015 :

Materials such as syringes, wrapped sterile and vials were not wiped down with Ster i le REDACTED (b)(4) prior to introduction into the REDACTED (b)(4) Incomplete sanitization of the stopper of each vial of drug product REDACTED (b)(4) Processing of product was performed on top of the sterile gloves wrapper, rather than worksurface. Gloves worn during processing in the REDACTED (b)(4) are not changed or sanitized with sterile REDACTED (b)(4) between production of different products and/or lots. · Disposable, non-sterile laboratory coats used during processing of drug products were reused, even after falling on the floor.

Observation 2

Drug products do not bear an expiration date determined by appropriate stability data to assure they meet applicable standards of identity, strength, quality and purity at the time of use.

Specifically, there is a lack of potency and sterility assurance for preserved and non-preserved sterile preparations in that beyond use dates, up to 3 months, are assigned without stability data and the container closure integrity of the bottles has not been established. Examples of products include : Buprenorphine (multidose vial) 0.3mg/mL, Lot # 02172015@24; Procain e (Buffered) (PF) 1% injectable, Lot# 04212015@17; Magnesium Sulfate Lot # 05202015@11; and Methylcobalamin(P ) 25mg/mL, Lot# 04302015@20; Cefazolin Ophthalmic (PF) 50mg/mL Solution, Lot# 04212015@26; and Methylprednison e (PF) eye drops, Lot# 05152015@1.

ster

Additionally, there is a l ack of test data to support that REDACTED (b)(4) , which have been REDACTED (b)(4) sterilized when produced, can be REDACTED (b)(4) to ensure sterility remains.

.t

Observation 3

Each batch of drug product purporting to be sterile is not laboratory tested to determine conformance to such requirements.

Specifically,

A . There is no documented test method for sterility testing for all products, except for Trimix (various formulations). The executed method has not been defined to be a compendial method or a method, which has been shown to be as good or better than the compendial method. In addition, on 6/29/2015, Pharmacist REDACTED (b)(4) failed to assure us that the executed sterility testing being performed was as per method suitability conducted by a contract testing laboratoty. Furthermore, negative controls are not run for each sterility test performed.

B. Endotoxin testing is not performed on all finished lots of drug products. For example REDACTED (b)(4) x10mL vials, with 5 mL in each vial, of Trimix lA Lot #04212015@10 were produced on 4/21/2015; however testing does not include en dotoxin results.

Observation 4

Equipment and utensils are not maintained at appropriate intervals to prevent malfunctions and contamination that would alter the safety, identity, strength, quality or purity of the drug product.

Specifically, balance REDACTED (b)(4) Model# REDACTED (b)(4), which is used to weigh non-sterile ingredie nts has not been calibrate d to ensure that the scale can we igh across its minimum range REDACTED (b) (4) The mini mum we ight used to calibrate the balance was REDACTED (b)(4) in 2014 and REDACTED ( b)(4) in 20 15 . Examples ofingredients which have been weighed that are les s than REDACTED (b)(4) include: REDACTED (b)(4)g procaine to compound procaine (buffered) (PF) 1% Lot# 04212015@17 and REDACTED (b)(4) of sodium molybdate REDACTED (b)(4) for Molybdenum(P) 25mcg/ML LOt # 06022015@5. Specifically, balance REDACTED (b)(4) Model# REDACTED (b)(4), which is used to weigh non-sterile ingredients has not been calibrated to ensure that the scale can weigh across its minimum range REDACTED (b)(4) The minimum weight used to calibrate the balance was REDACTED (b)(4) in 2014 and REDACTED (b)(4) in 2015. ...

Read the full 483 (PDF on fda.gov)

Observation 5

Employees are not given training in the particular operations they perform as part of their function.

Specifically,

A. There is no documented microbiological training for the following tests and individuals who perform them:

1. Sterility and environmental testing by Pharmacist, REDACTED (b)(4). 2. Reading of microbiological assay results by Pharmacy Technician REDACTED (b)(4). 3. Performance of REDACTED (b)(4) by Pharmacist Intern, REDACTED (b)(4).

B. There is no documented training for Pharmacist REDACTED (b)(4) who performed physical testing for sterile compou nded finished products.

Observation 6

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions . .

Specifically,

A. Procedure SOP 3.03 Environmental Monitoring (EM) ofthe Sterile Compounding Area (Date Effective: 01-01-07) provides instructions on surface sampling technique and incubation; however, this procedure is not being followed. For example: use of environmental monitoring sampling supplies are not the same as described in the procedure, REDACTED (b)(4) was observed to be sampling multiple loca tions in th e REDACTED (b)(4 ) and all EM samples are not being incubated for the REDACTED (b)(4) temperature requirement.

Procedure SOP 3.03 Environmental Monitoring (EM) ofthe Sterile Compounding Area (Date Effective: 01-01-07) provides in structions on surface sampling technique and incubation; however, this procedure is not being followed. For example: use of environmental monitoring sampling supplies are not the same as described in the procedure, REDACTED (b)(4) was observed to be sampling multiple locations in the REDACTED (b)(4) and all EM samples are not being incubated for the REDACTED (b)(4) temperature requirement.

B. ...

Read the full 483 (PDF on fda.gov)

Observation 7

There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

Specifically, for at least two products which the firm has tested, including Alprostadil 10mcg/mL Lot# 012420I2@I and Meth ylcobalamin(P) 25mcg/mL Lot# 12042013@59, the testing for these lots resulted in a potency outside of 139% and 72%, respectively. Methylcobalamin(P) 25mcg/mL Lot# 12042013@59 was not dispensed; however the firm has produced this formulation since and has dispensed it as Lot# 06042015@37 without ensuring that the potency is within specifications.

• Alprostadil l0mcg/mL Lot # 01242012@1, tested on 1/26/2012, resulted in a potency of 139%. The product was di spensed to a patient on 1/23/2012. • Methylcobalamin(P) 25mcg/mL Lot# 12042013@59, tested on 1/16/2014, resulted in a potency of 72.2%. The lot was not dispensed; however the firm has produced this formulation since without investigating the failure. Most recently , Methylcobalamin(P) 25mcg/ml has been dispensed as Lot# 06042015@37 ...

Read the full 483 (PDF on fda.gov)

Observation 8

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the equipment to produce aseptic conditions.

Specifically, the firm has not demonstrated the efficacy of their disinfectants, REDACTED ( b)(4), Steri le REDACTED (b)(4) and Sterile REDACTED (b)(4) %, which are used to clean the firm's REDACTED (b)(4) and ISO 8 anteroom.

Additionally, we did not observe personnel adhhering to the established contact times for their disinfectant agents as noted in

SOP 3. 02 Cleaning and Ma intenance o f the Clean Room facility (Date Effective: 01-01-07).

Observation 9

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactor y conformance to the final specifications prior to release.

Specifically,

A. Visual inspection ofAlprostadil 20mcg/mL Lot# 06252015@31 on 6/29/2015 was not documented within the batch

record as per procedure SOP 6.02 Sterile Compounding Finished Preparation Testing (Date Effective: 01-01-07). This p roduct was delivered to the customer on 6/30/2015.

B. During compounding of TriMix STD Mayo Lot# 06302015@14, we observed that the operator did not conduct a visual check of REDACTED (b)(4) to REDACTED (b)(4) ofPhentolami ne. There are no procedures to ensure that this quality control step is taken REDACTED (b)(4). We observed non-dissolved in the REDACTED (b)(4)

Observation 10

Procedures designed to prevent microbiologicaJ contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process.

Specifically, media fill simulations are not representive of the preparation ofa

septically fil led sterile products. For example, the sterile preparation of REDACTED (b)(4) Trimix 1A RX (PAPAV/PHENTOL/PGE1) 30MG/IMG/IOMCG/mL has REDACTED (b)(4) however, the media fill simulation is REDACTED (b)(4)

Observation 11

The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.

Specifically, you have not qualified or audited your contract testing laboratories, used for potency, endotoxin, and sterility testin of Trimix finished products; however rely on their results.

Observation 12

The flow ofcomponents, drug product containers, in-process materials, and drug products though the building is not designed to prevent contamination.

Specifically, the ISO 8 anteroom contains a sink sourced with tap water that is located REDACTED (b)(4) w hich is used as the REDACTED (b)(4) the firm's REDACTED (b)(4)

Linked 483s whose text is not shown

State board of pharmacy records

State board of pharmacy records for New Jersey are not checked: the Division of Consumer Affairs website, which publishes pharmacy permit records and board actions, answers automated requests with a bot challenge, and the state’s public license lookup lists individual licensees but not pharmacy permits; this index does not work around blocks.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

Texas State Board of Pharmacy, file dated Nov 15, 2026 (Texas).

LicenseType as the board gives itName on the board recordLocationStatusPrior disciplinary orders (file flag)
35591Non Resident Sterile CompoundingMILLERS OF WYCKOFF INCWYCKOFF, NJActiveNo

California State Board of Pharmacy, file dated Nov 6, 2026 (California).

LicenseType as the board gives itName on the board recordLocationStatus
NRP 2219Non Resident PharmacyMillers Of Wyckoff IncWyckoff, NJActive

Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).

LicenseType as the board gives itName on the board recordLocationStatus
OSP 6085OSPMillers of Wyckoff IncWyckoff, NJActive

Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).

LicenseType as the board gives itName on the board recordLocationStatus
054023595LICENSED PHARMACYMILLERS OF WYCKOFF INCWYCKOFF, NJACTIVE
054018003LICENSED PHARMACYMILLERS OF WYCKOFF INCWYCKOFF, NJCHANGE OF OWNERSHIP
054021124LICENSED PHARMACYMILLERS OF WYCKOFF INCWYCKOFF, NJCHANGE OF OWNERSHIP
054023471LICENSED PHARMACYMILLERS OF WYCKOFF INCWYCKOFF, NJCHANGE OF OWNERSHIP

Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).

LicenseType as the board gives itName on the board recordLocationStatus
PCN.0000894NONRESIDENT PHARMACYMILLERS OF WYCKOFFWYCKOFF, NJACTIVE (CURRENT)

Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).

LicenseType as the board gives itName on the board recordLocationStatus
A9-0013192Non Resident PharmacyMillers of WyckoffWYCKOFF, NJActive
A9-0001121Non Resident PharmacyMillers of WyckoffWyckoff, NJClosed
A9-0002292Non Resident PharmacyMillers of WyckoffWYCKOFF, NJClosed

Michigan Department of Licensing and Regulatory Affairs, file dated Nov 10, 2026 (Michigan).

LicenseType as the board gives itName on the board recordLocationStatus
5301009862PharmacyMillers of Wyckoff, Inc.Wyckoff, NJActive

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.